Ocuphire Pharma

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Ocuphire Pharma, Inc. (OCUP) Just Flashed Golden Cross Signal: Do You Buy?

FARMINGTON HILLS, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, founder and CEO will present at several investor conferences in November and December, including the BTIG Ophthalmology Day, Alliance Global Partners (AGP) Biotech Conference, Ophthalmology Innovation Summit (OIS XII), Cantor Dermatology, Ophthalmology & Medtech Conference, and the Planet MicroCap Conference, being held on the following dates:

Ocuphire to Present at Five Upcoming Investor/Industry Conferences

Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022

Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update

FARMINGTON HILLS, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the positive results in night vision disturbances (NVD) patients from its earlier and first Phase 2 study evaluating the safety and efficacy of phentolamine mesylate eye drops (Nyxol) have been peer-reviewed and published in BMC Ophthalmology.

Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)

Ocuphire Pharma, Inc. (OCUP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Ocuphire Pharma, Inc. (OCUP) Rating Upgrade to Buy

FARMINGTON HILLS, Mich., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced acceptance and presentation of six posters featuring Nyxol® and APX3330 at the American Academy of Optometry (AAOPT) 2022 Annual Meeting being held October 26-29, 2022 in San Diego, CA.

Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting

Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CT Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CT

Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

Virtual Webinar to Take Place Friday, October 14 th @ 11 AM ET

Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease

FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has appointed seven new Key Opinion Leaders (KOLs) across retina, cornea/refractive, and medical optometry to its Medical Advisory Board (MAB). In addition, Ronil Patel, M.S. has been promoted to Vice President, Business Development and Market Strategy.

Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team

FARMINGTON HILLS, Mich., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, CEO and Founder will present a company overview at the Ophthalmology Futures Forums European Forum 2022 on September 15, 2022. At the Eyecelerator@AAO 2022 on September 29, 2022, Mina Sooch will present an overview of the Nyxol program and Bindu Manne, Head of Market Development and Commercialization, will participate on an ophthalmology leadership panel. In addition, clinical data on its late-stage candidate Nyxol will be featured in a poster presentation by Mitchell Jackson, MD at the upcoming American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30, 2022 – October 3, 2022 in Chicago.

Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022 NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022

Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA

Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

FARMINGTON HILLS, Mich., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, Founder and CEO will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.

Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference

Completed Final Clinical Trials and Pre-NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (RM), On Track for Late 2022 NDA Submission and Potential 2023 Approval

Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update

Canaccord Genuity 42 nd Annual Growth Conference on August 10, 2022

Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August

Issuance Extends Nyxol's U.S. Patent Protection from 2034 into 2039 for RM Indication

Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance

Mina Sooch CEO to Present at Ophthalmic Innovation Panel at the 11 th Annual AECOS Summer Symposium and OIS Retina Innovation Summit

Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July

Newly Issued Patent Broadens Medical Uses of Oral APX3330 Therapy in Patients with Diabetes and Extends Expiry Thru 2038

Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication

Of 103 Diabetic Subjects Enrolled in the 24-week ZETA-1 Phase 2b Trial, 70% Have Completed 12 or More Weeks

Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting

Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo

Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months

Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update

FARMINGTON HILLS, Mich., May 11, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations by Mina Sooch, Founder and CEO, at the New Pathways in Retinal Diseases Panel at Retina World Congress (RWC) on May 12, 2022 and at H.C. Wainwright Global Investment Conference on May 24, 2022. Dr. David Lally will also be presenting masked safety data from Phase 2b APX3330 trial at RWC and Clinical Trials at the Summit on May 21, 2022.

Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference

Nyxol Demonstrated a Favorable Safety Profile and Rapidly Reversed Dilated Eyes in Pediatric Subjects 3 to 11 Years Old, Consistent with Findings in MIRA-2 and MIRA-3 Phase 3 Registration Trials

Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

Four ARVO presentations accepted will feature data from APX3330 Phase 2b trial in Diabetic Retinopathy and Nyxol® Phase 2 trial in Presbyopia and Phase 3 trial in Reversal of Mydriasis Four ARVO presentations accepted will feature data from APX3330 Phase 2b trial in Diabetic Retinopathy and Nyxol® Phase 2 trial in Presbyopia and Phase 3 trial in Reversal of Mydriasis

News for Ocuphire Pharma Stock (OCUP)